References
- Solimini R, Rotolo MC, Pellegrini M, et al. Adulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol. 2017;18(7):524–530.
- Marquez J, Aguirre L, Muñoz C, et al. Cocaine-Levamisole-induced vasculitis/vasculopathy syndrome. Curr Rheumatol Rep. 2017;19(6):36.
- Di Trana A, Montanari E. Adulterants in drugs of abuse: a recent focus of a changing phenomenon. Clin Ter. 2022;173(1):54–55.
- Bourmaud A, Dahm G, Meys F, et al. Investigation on heroin and cocaine quality in Luxembourg. Harm Reduct J. 2021;18(1):97.
- Barbera N, Busardò FP, Indorato F, et al. The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome. Forensic Sci Int. 2013;227(1–3):74–76.
- Gleason B, West A, Avula D, et al. Collaborative public health investigation of Clenbuterol-adulterated heroin outbreak-Richmond, Virginia, March–April 2015. J Public Health Manag Pract. 2017;23(2):e8–e11.
- Kelkar AH, Smith NA, Martial A, et al. An outbreak of synthetic cannabinoid–associated coagulopathy in Illinois. N Engl J Med. 2018;379(13):1216–1223.
- Arepally GM, Ortel TL. Bad weed: synthetic cannabinoid-associated coagulopathy. Blood. 2019;133(9):902–905.
- Devgun JM, Rasin A, Kim T, et al. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides. Clin Toxicol. 2020;58(8):821–828.
- Fauconnet V, Pouliquen H, Pinault L. Reversed-phase HPLC determination of eight anticoagulant rodenticides in animal liver. J Anal Toxicol. 1997;21(7):548–553.
- O’Bryan SM, Constable DJ. Quantification of brodifacoum in plasma and liver tissue by HPLC. J Anal Toxicol. 1991;15(3):144–147.
- Konakion® MM 10 mg Prescribing Information, Cheplapharm Arzneimittel GMBH, Germany. [Internet]. Available from: https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum01_5_925303422.pdf.
- Chong YK, Mak TWL. Superwarfarin (Long-Acting anticoagulant rodenticides) poisoning: from pathophysiology to Laboratory-Guided clinical management. Clin Biochem Rev. 2019;40(4):175–185.
- Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives. Bioorg Med Chem. 2007;15(6):2414–2420.
- Watt BE, Proudfoot AT, Bradberry SM, et al. Anticoagulant rodenticides. Toxicol Rev. 2005;24(4):259–269.
- Fasih A. Lethal coagulopathy resulting from the consumption of contaminated synthetic cannabinoids: the story of a public health crisis. J Public Health. 2021;43(1):E1–E6.
- World Health Organization & International Programme on Chemical Safety. Brodifacoum: health and Safety guide [Internet]. World Heal. Organ. 1995]; cited 2023 Jan 31]; Available from https://apps.who.int/iris/handle/10665/36901.
- Waien SA, Hayes D, Leonardo JM. Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide. N Engl J Med. 2001;345(9):700–701.
- La Rosa FC, Clarke SH, Lefkowitz JB. Brodifacoum intoxication with marijuana smoking. Arch Pathol Lab Med. 1997;121(1):67–69.
- Moritz E, Austin C, Wahl M, et al. Notes from the field: outbreak of severe illness linked to the vitamin K antagonist brodifacoum and use of synthetic Cannabinoids – Illinois, March–April 2018. MMWR Morb Mortal Wkly Rep. 2018;67(21):607–608.
- Wright E, Hafner JW, Podolej G, et al. Severe vitamin K-dependent coagulopathy from rodenticide-contaminated synthetic cannabinoids: emergency department presentations. West J Emerg Med. 2021;22(4):1014–1019.
- Ross CH, Singh P, Simon EL. Hemorrhagic soft tissue upper airway obstruction from Brodifacoum-contaminated synthetic cannabinoid. J Emerg Med. 2019;57(1):47–50.
- Tole M, LaBedz S, Feinstein DL, et al. Adherence to long-term follow-up of patients with life-threatening, inhaled synthetic Cannabinoids-associated coagulopathy in chicago. Lung. 2019;197(3):349–352.
- Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425–435.
- Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol. 2014;52(7):664–673.
- Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use–multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(6):93–98.
- Feinstein DL, Nosal DG, Ramanathan S, et al. Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. Clin Toxicol. 2020;58(7):716–724.
- Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med. 1993;153(16):1925–1928.
- Park BK, Scott AK, Wilson AC, et al. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol. 1984;18(5):655–662.
- Schurgers LJ, Teunissen KJF, Hamulyák K, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K 1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279–3283.
- Afanasjeva J. Administration of injectable vitamin K orally. Hosp Pharm. 2017;52(9):645–649.
- Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469–2473.
- van Rein N, Gebuis EPA, Lijfering WM, et al. Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects. J Thromb Haemost. 2014;12(12):2017–2023.
- Yip L, Stanton NV, Middleberg RA. Vitamin K 1 treatment duration in patients with brodifacoum poisoning. N Engl J Med. 2020;382(18):1764–1765.